Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of unresectable Stage IIIb not amenable to treatment with combined modality chemoradiation (advanced) or Stage IV (metastatic) NSCLC
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
Measurable disease
Adequate recovery from most recent systemic or local treatment for cancer
Adequate organ function
Life expectancy greater than or equal to (\>/=) 12 weeks
For female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception
You may not be if
Inability to swallow oral medication
Women who are pregnant or lactating
Symptomatic, untreated CNS metastases
History of malignancy other than NSCLC within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death
Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina
Known active or uncontrolled human immunodeficiency virus (HIV) infection
Either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study
Inability to comply with other requirements of the protocol
Clareo Health | A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
